Document is current
Any future updates will be listed below
-
Authors
Veldkamp, Kars I.
Evers, Luc J. W.
van Laarhoven, Twan
Raykov, Yordan P.
Little, Max A.
Ho, King Chung
Shin, Sooyoon
Lehmann, Lisa Soleymani
Bloem, Bastiaan R.
Brouwer, Marc A.
Thannhauser, Jos
- License Information
-
More Information
Article History
Received: 15 August 2025
Accepted: 13 April 2026
First Online: 19 May 2026
Declarations
Ethics approval and consent to participate: The Personalized Parkinson Project was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines, and were approved by the local medical ethics committee (Commissie Mensgebonden Onderzoek, regio Arnhem-Nijmegen, reference number 2016–2934). All participants provided informed consent prior to enrollment.
Consent for publication: All authors have read and approved the final manuscript, and consented to its publication.
Competing interests: Authors KCH, SS and LSL are currently employed by, and currently hold shares in, Verily Life Sciences, but declare no nonfinancial competing interests. Author BRB serves as the co-Editor in Chief for the Journal of Parkinson’s disease, serves on the editorial board of Practical Neurology and Digital Biomarkers, has received fees from serving on the scientific advisory board for the Critical Path Institute, Gyenno Science, MedRhythms, UCB, Kyowa Kirin and Zambon (paid to the Institute), has received fees for speaking at conferences from AbbVie, Bial, Biogen, GE Healthcare, Oruen, Roche, UCB and Zambon (paid to the Institute), and has received research support from Biogen, Cure Parkinson’s, Davis Phinney Foundation, Edmond J. Safra Foundation, Fred Foundation, Gatsby Foundation, Hersenstichting Nederland, Horizon 2020, IRLAB Therapeutics, Maag Lever Darm Stichting, Michael J Fox Foundation, Ministry of Agriculture, Ministry of Economic Affairs & Climate Policy, Ministry of Health, Welfare and Sport, Netherlands Organization for Scientific Research (ZonMw), Not Impossible, Parkinson Vereniging, Parkinson’s Foundation, Parkinson’s UK, Stichting Alkemade-Keuls, Stichting Parkinson NL, Stichting Woelse Waard, Health Holland / Topsector Life Sciences and Health, UCB, Verily Life Sciences, Roche and Zambon. Author BRB does not hold any stocks or stock options with any companies that are connected to Parkinson’s disease or to any of his clinical or research activities. All other authors declare no competing interests.
